Fundraising Fox
ARCA biopharma
Westminster, US · Delaware corporation · 1 known investors
Find your way into ARCA biopharma
Sign up to see every warm intro you have to ARCA biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ARCA biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oruka is a biopharmaceutical company developing monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions, aiming for high rates of disease clearance with as few as one or two doses per year. Its pipeline includes ORKA-001 and ORKA-002, both in clinical trials for moderate-to-severe plaque psoriasis.
Founders & leadership
MR
Michael R. BristowFounder
TA
Thomas A. KeuerExecutive
BL
Brian L. SelbyExecutiveBrian L. Selby is an Executive Officer at ARCA biopharma (Oruka), a biopharmaceutical company developing monoclonal antibodies for dermatologic and inflammatory conditions. He has experience in financial operations, capital raising, and building financial infrastructure at early-stage companies.
PM
Patrick M. WheelerExecutive
CD
Christopher D. OzeroffNamed on SEC filing
Board
DJ
Dan J. MitchellBoard director
JF
Jean-Francois FormelaBoard director
RL
Raymond L. WoosleyBoard director
LS
Linda S. GraisBoard director
RE
Robert E. ConwayBoard director
RB
Richard B. BrewerBoard director
JL
John L. ZabriskieBoard director
Investors · 1
Boulder VenturesreportedBoulder · $1M – $4M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$56.5M disclosed across 3 rounds · 2011–2015
▶$51.7MraisedJun 2015 · 14 investors · PharmaceuticalsRule 506(b)
▶$51.7MraisedJun 2015 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher D. OzeroffExecutive Officer
- Thomas A. KeuerExecutive Officer
- Raymond L. WoosleyDirector
- Linda S. GraisDirector
- Dan J. MitchellDirector
- Brian L. SelbyExecutive Officer
- Robert E. ConwayDirector
- Michael R. BristowExecutive Officer, Director
- Offering amount
- $51.7M
- Amount sold
- $51.7M
- Sales commissions
- $2.6M
- Placement agents
- MTS Securities, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$326.2KraisedFeb 2014 · 2 investors · PharmaceuticalsRule 506(b)
▶$326.2KraisedFeb 2014 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael R. BristowExecutive Officer, Director
- Robert E. ConwayDirector
- Linda S. GraisDirector
- Raymond L. WoosleyDirector
- Christopher D. OzeroffExecutive Officer
- Patrick M. WheelerExecutive Officer
- Offering amount
- $326.2K
- Amount sold
- $326.2K
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJan 2012 · 6 investors · PharmaceuticalsRule 506(b)
▶$4.5MraisedJan 2012 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael R. BristowExecutive Officer, Director
- Richard B. BrewerDirector
- Jean-Francois FormelaDirector
- Linda GraisDirector
- Patrick M. WheelerExecutive Officer
- John L. ZabriskieDirector
- Burton E. SobelDirector
- Christopher D. OzeroffExecutive Officer
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Sales commissions
- $97.5K
- Placement agents
- Roth Capital Partners LLC
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does ARCA biopharma do?
- Oruka is a biopharmaceutical company developing monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions, aiming for high rates of disease clearance with as few as one or two doses per year. Its pipeline includes ORKA-001 and ORKA-002, both in clinical trials for moderate-to-severe plaque psoriasis.
- Who founded ARCA biopharma?
- ARCA biopharma was founded by Michael R. Bristow.
- Who are ARCA biopharma's investors?
- ARCA biopharma's investors include Boulder Ventures.
- How much funding has ARCA biopharma raised?
- ARCA biopharma has disclosed $56.5M raised across 3 rounds.
- Where is ARCA biopharma headquartered?
- ARCA biopharma is headquartered in Westminster, US.